Probiotic-guided CAR-T cells for solid tumor targeting

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,847

The microbiome and human cancer

Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272

Tumor Antigen Escape from CAR T-cell Therapy

Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,233

The Principles of Engineering Immune Cells to Treat Cancer

Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,103

Engineering the perfect (bacterial) cancer therapy

Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833

The role of 131I in the treatment and management of thyroid cancer

Rais, J., Gambhir, S., & Dixit, M. (2025) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2025.100009 · Cited by 1

Bioengineered Escherichia coli Nissle 1917 with hematoporphyrin monomethyl ether for targeted sonodynamic therapy and immune activation in ovarian cancer

Pei, Y., Huan, Y., Chen, L., Zheng, X., & Liu, B. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02928g · Cited by 1

Next-generation in vivo CAR-T expansion strategies: Unlocking durable anti-tumor responses in solid tumors

Sun, Z., Wei, L., Pan, X., Yan, W., Wang, T., & Wang, X. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105342 · Cited by 1

Octopus-inspired engineered bacteria with a plug-and-play surface display system achieves enhanced tumor-specific colonization and antitumor immunity

Wu, L.-Y., Qiu, J.-H., Qiao, X.-Y., Li, L. Z., Qiao, L.-Y., Li, C.-Y., Sun, Y., Zhang, S.-H., Du, Z.-Z., Chang, X.-Y., et al. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100030 · Cited by 1

Immunomodulatory microbials for cancer immunotherapy: A mini review

Hou, Y., Shi, Y., & Yang, Y. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112912 · Cited by 1

Programmable living therapeutics for cancer immunotherapy

Deng, Z., Niu, L., Wang, Z., Jin, Y., Yao, Z., Wan, H., Guan, N., & Ye, H. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.04.007 · Cited by 2

A Probiotic Approach Targeting Hypersialylation Revives CD8+ T-cell Immunity and Boosts Photodynamic Therapy Efficacy in Solid Tumors

Wang, Y., Chen, X., Zhang, W. T., Zhou, W., Zhang, S., 党双锁, Ma, Y., Miao, Y., Wu, C., Liu, C., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3070 · Cited by 1

Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation

Zhao, N., Wu, L., Peng, S., Yang, H., 宋永春, Zhang, Y., & Ding, L. (2026) · Biomarker Research · doi:10.1186/s40364-026-00930-2 · Cited by 2

Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence

Behl, A., & Sharma, K. K. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11077-9 · Cited by 1

Bacterial engineering for cancer therapy

Chen, N., Yang, Z., & Arpaia, N. (2026) · Nature Cancer · doi:10.1038/s43018-026-01171-w · Cited by 2

Engineered photothermal-responsive bacterial platform for in vivo fluorescence imaging-guided photothermal/gene combined breast cancer therapy

Zhang, J., Guo, B., Wang, Z., Zhang, F., Shi, X., Hu, C., Yang, Z., Shen, Y., & Wang, F. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.05.022 · Cited by 1

Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study

Xu, Y., Xu, Y., Wang, Z., Yi, Q., Wang, F., & 卞坡 (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2690841 · Cited by 1

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Chen, H., Luo, X., Gao, H., Ke, Y., Zhan, Y. Q., Xu, X., Xiong, X., Wei, F., Yang, S., Liu, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.75993 · Cited by 1

Progress in engineered bacterial cancer therapies

Pico-Sánchez, E., & Fernández, L. Á. (2026) · Current Opinion in Microbiology · doi:10.1016/j.mib.2026.102785 · Cited by 1

Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types

Yang, X., Yin, Q., Li, K., Wang, J., Song, R., Zhou, H., Han, S., Zhang, L., Zeng, Y., Xu, D., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.07.015 · Cited by 1

Microbial indole-3-acetamide alleviates polycystic ovary syndrome through HIF-2α-ceramide signaling

Chen, W., Zhao, M., Yan, S., Li, M., Ye, C., Yun, C., Zhang, L., Mao, Y., Yan, Z., Wen, Y., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.08.015 · Cited by 2

Engineered probiotics for tumor-targeted combination chemoimmunotherapy

Yang, Z., Im, J., Chen, N., Mariuzza, D. L., Santos, K. D. L., Li, F., Ballister, E. R., Ringham, O. R., Danino, T., & Arpaia, N. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady2289 · Cited by 2

Bacteria tag tumours for CAR-T cell attack

Villanueva, M. T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/d41573-023-00181-y · Cited by 1

Bacteria displaying cytokines heat up the tumor microenvironment

Fidelle, M., & Zitvogel, L. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02429-3 · Cited by 1

Immune cell and engineering for the therapeutics

Jeong, J. H., Kim, M., & Li, H.-S. (2024) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2024.100569 · Cited by 1

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer

Ho, M. P., & Bonavida, B. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025058633 · Cited by 1

Bacteria tag tumours for CAR T cell attack

Villanueva, M. T. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00971-w

Redefining Cancer Battlefields: Novel CAR T-cell Therapies in Solid Tumor Warfare

Yeh, A. C., & Markey, K. A. (2024) · The Hematologist · doi:10.1182/hem.v21.1.202413

Probiotic Interventions in Cancer

Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_11

Cancer Therapies

Vela, V., Sabani, B., & Spahn, G. (2025) · Springer eBooks · doi:10.1007/978-3-031-84297-9_6

Microbiome and Cancer

Righetti, F., Massara, M., & Calcinotto, A. (2025) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-031-84065-4_8

INNOVATIVE STRATEGIES FOR IMPROVING PROBIOTIC VIABILITY USING AVOCADO-BASED PREBIOTICS AND NANOTECHNOLOGY

JATIN, M., ADHIKARI, B., Johnson, A. B., KUMAR, P., & Rajeshkumar, R. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.54336

Adoptive T cell therapy in cancer: Mechanisms, challenges, and future innovations

Zhou, Q. P., Li, C., & Wu, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00049-7

Krebstherapien

Vela, V., & Spahn, G. (2025) · Springer eBooks · doi:10.1007/978-3-662-70291-8_6

Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer ImmunotherapyPreprint

Gottipamula, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7408618/v1

In Vitro Generation of Enhanced or Engineered Platelets

Wu, H., Taylor, L. C., & Deans, T. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_17

Cancer cell-selective ecotopic expression of CD20 as an antigen enables rituximab repurposing for solid tumor immunotherapyPreprint

Kong, Z., Wang, Y., Zhao, Y., Wang, L., Fan, Z., Shu, Y., & Wang, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682764

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Wright, J. A., & Woods, S. L. (2025) · doi:10.64628/aa.r9cugrp35

Genetically encoded biosensors in microbes for Tumor targeting

Chen, X., Zhou, Y., Han, X., Xiao, T., & Lyu, X. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118244

Pluronic nanoparticle-modified modular bacterial robots for therapy of tumors and inflammatory bowel disease

Fan, J., Huang, L., Liu, M., Liu, H., & Wu, D. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb02037a

Exosome‐Inspired Proteolipid Nanoparticles Enable Safe, Extrahepatic RNAi–Chemo Therapy Through Cholesterol‐Free, Tumor‐Preferential Delivery

Ren, Y., Wang, Q., Li, P., Zhang, Z., Wei, G., Tan, Y., Moon, W., Kim, P., Sun, X., Kang, F., et al. (2026) · Advanced Healthcare Materials · doi:10.2139/ssrn.5400816

Biohybrid miniature robots using living organisms

Zhang, M., Zhong, W., Chen, W., Wang, H., He, J., Liu, Z., Uthappa, U. T., Guo, Z., & Wang, B. (2026) · International Journal of Extreme Manufacturing · doi:10.1088/2631-7990/ae34f9

Real-time multimodal phenotyping reveals distinct tumour cell dynamics and immune escape mechanisms in T cell therapies

Chen, S., Yu, K., Zhang, S., Guo, X., & Zhu, R. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01582-7

Live biotherapeutics in cancer therapy

Mishra, R., Kumar, S. S., Panda, T. S., Mahapatra, S., & Prasad, P. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.002

Aiming allogeneic γδ T cells with tumor-specific antibodies via bioorthogonal chemistry for enhanced solid tumor immunotherapy

Zheng, M., Yang, Z., Wang, D., Aili, A., Li, H., Pan, L., Gao, Z., Lin, J., & Chen, L. (2026) · Chemical Engineering Journal Advances · doi:10.1016/j.ceja.2026.101084

Intratumoral bacteria engineered for tumor therapy

Zhang, H., Chen, Z., Yao, Z., Luo, S., Luo, C., Yang, R., Fu, H., & Huang, S. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70106

Photoactivated probiotic micro-reactor synchronizes STING/TLRs agonists to spatiotemporally synergize antitumor immunotherapy

Qiu, Y., Liu, Y., Chen, S., Liu, Y., Yu, X., Yang, X., Zhang, Y., & Zhu, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04300-w

Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors

Shabiti, S., Pan, H., Xu, X. X., Xu, S., Xu, Z., Zheng, J., Zhang, X., Li, F., Ke, Y., Wang, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c00238

Immunotherapy for Leiomyosarcoma: Current Status and Perspectives

Qi, H., Zhang, H., Wang, Q., Wang, X., Min, L., Zhou, Y., Liu, B., & Li, R. (2026) · Journal of Immunology Research · doi:10.1155/jimr/6614578

Remodeling of capsular polysaccharide enhances colonization and therapeutic efficacy of probiotic Escherichia coli against colitis

Liu, X., Liu, Z., Li, H., He, Y., Shu, T., Li, J., Wang, Y., Song, Y., Zhang, J., Tan, H., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124347

Lactate‐Depleting Engineered Probiotics Remodel the Tumor Microenvironment and Enhance PD‐1 Blockade

Zhang, J., Zhang, Q., Liu, Y., Dai, Y., Teng, X., & Li, J. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71316 · Cited by 1

Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology

Liu, X., Zhang, H., Du, R., Liu, Z., Ren, Y., & Yang, X. S. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683171

EPIC: multi-objective guided diffusion for epitope design in TCR-pMHC complexes

Huang, Y., Yu, G., Chen, L., Luan, H., & Yang, Y. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag358

In Situ Biosynthesis of Pd Nanocrystals in Bifidobacterium Bioreactor as Dual Immune Stimulators for Immuno‐Chemodynamic Therapy of Cold Tumor

Zhang, F., Peng, Z., Zhang, C., Zhang, Z., Yang, W., Xu, J., Li, G., Wang, X., Wang, L., & Xie, W. (2026) · Small · doi:10.1002/smll.74027

T cell control of the intestinal barrier and gut microbiota during ageing

Heras, M. M. G. D. L., & Mittelbrunn, M. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.05.001

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models

Rouanne, M., Chen, N., Mariuzza, D. L., Yang, Z., Li, F., Santos, K. D. L., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv7600 · Cited by 2

Programmable Encapsulation Enables On‐Demand Proliferation of Therapeutic Bacteria for Potent Cancer Immunotherapy

Yang, J., Peng, A., Li, S., Huang, Y., Yan, J., Wang, L., Zhu, Z., Liu, F.-L., Bian, E., Liu, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.76706

IGHG1⁺ plasma cells define an NF-κB-driven inflammatory program that shapes T-cell immunity and immunotherapy response in colorectal cancer

Zhang, R., Zhang, W.-Z., Li, H., Chen, Y., Zhong, R., & Wang, J. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102930

Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers

Kong, Z., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891408

Engineered microorganisms and nanomaterials in cancer therapy: Emerging hybrid systems and translational challenges

Cheng, Y., 余申翰, Huang, Y., & Liu, B. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103002

Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions

Raza, A., Raza, M. A., Khan, J., & Ajazuddin (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156645

Tumor-tropic E. coli engineered as living T and NK cell engagersPreprint

Yang, S., Bader, A. C., Sendker, S., Hu, A., Chen, D. C., Nath, H., Chen, A., Bobilev, E., Sheffer, M., Hui, V. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.18.745642

A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens

Guo, L., Xie, H., Yin, D., Zhu, G., Zhai, P., Pei, G., Zhang, W., Xiao, F., Lyu, J., & Tang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919208

Cell Engineering

Zhang, W. (2026) · Springer eBooks · doi:10.1007/978-3-032-32096-4_6

Cancer cell‐selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy

Kong, Z., Wang, Y., Zhao, Y., Wang, L., Fan, Z., Shu, Y., & Wang, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70804

Allogeneic CAR-T cell engineering: immune stealth, product fitness, and clinical translation

Yang, R., Mi, X., Li, Z., Yan, K., & Xiao, Z. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103005

Neutrophil-Inspired Programmable Bacteria for Pyroptosis-Driven Tumor Eradication

Zhang, J., Chen, S., Wang, X., Shi, J., Dong, C., Guo, J., Xie, H., Lei, H., Zhu, Y., & Wu, Y. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c16051

A bio-orthogonally engineered probiotic-T cell chimera amplifies adoptive cell therapy through spatial DC-T cell immune licensing

Shen, J., Chu, Y., Wang, Y., Chen, X., Ke, Y., Huo, D., Zhu, J., Hong, S., Qin, S., Liu, B., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.09.009

Microbial Signals in Cancer: Dissecting Host–Microbiota–Tumor Interactions and Potential Therapeutic Strategy

Lu, J., Xuan, M., Yu, L., Xie, Z., Chu, Q., Wei, S., Wang, T., Xue, C., & Li, L. (2026) · MedComm · doi:10.1002/mco2.70994

Probiotics-Driven Type I Photosensitizer for Tumor-Targeted Fluorescence Imaging and Photodynamic Immunotherapy

Zhao, J., Pan, X., Chen, Y., Feng, S., & Wu, M. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c04528

Bacterial metabolic–immune reprogramming in cancer: from living vectors to engineered biofactories

Wu, J., Xu, L., Chen, Q., Yu, L., Liu, Z., & Xia, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115394

Intratumoral Microbiota in Fueling Cancer and Steering Treatment Response

Xu, M., Yu, J., Chen, Y., Ge, S., Ye, L., Wang, Y., 周一雄, & Jia, R. (2026) · MedComm · doi:10.1002/mco2.71052

From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer Outcomes

Nassar, S. A. (2026) · Medical Sciences · doi:10.3390/medsci14060669

Scalable cultured gut microbiota-derived nanovesicles for oral augmentation of checkpoint blockade therapy

Chen, L., Tayier, N., Wu, H., Liu, G., Wang, S., Zhu, Y., Sun, J., Niu, Y., Feng, C., You, L., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115456

From Passive Carriers to Niche Engineers: The Evolving Paradigm of Engineered Bacteria in Cancer Therapy

Liang, Y., Ning, Z., Su, B., Liang, N., Zhu, F., & Sun, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111354

Programmable Engineered Living Vehicles as Autonomous Biofactories for Synergistic Osteomyelitis Management and Bone Regeneration

Lan, Y., Liu, X., Zhifeng, S. H. I., Li, Y., Chi, A., Zheng, J., Tan, Y., Xiao, C., Zheng, R., Yang, Y., et al. (2026) · Advanced Materials · doi:10.1002/adma.75118

Mapping engineered-bacteria research identifies drug delivery and cancer therapy as emerging translational frontiers

Wang, J., Qi, R., Chang, T., & Zhang, Y. (2026) · Engineering Microbiology · doi:10.1016/j.engmic.2026.100311

Probiotic-guided CAR-T cells for universal solid tumor targetingPreprint

Vincent, R. L., Gurbatri, C. R., Redenti, A., Coker, C., Arpaia, N., & Danino, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.10.463366 · Cited by 13

Abstract 5237: Engineered probiotics direct the antigen specificity of CAR-T cells in situ

Vincent, R. L., Li, F., Vardoshvili, A., Gurbatri, C. R., Arpaia, N., & Danino, T. (2024) · Cancer Research · doi:10.1158/1538-7445.am2024-5237 · Cited by 3

Probiotic-Guided CAR T cells Promote Antigen-Agnostic Solid Tumor Cytotoxicity

(2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2023-170

Bacteria tag tumours for CAR-T cell attack

Villanueva, M. T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/d41573-023-00181-y · Cited by 1

Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?

Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 29